Page last updated: 2024-12-07
xymedon
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
xymedon: nitrogen-containing heterocyclic compound; Russian patent; antiatherogenic; used for treatment of burns; used on varicose ulcer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 121931 |
| CHEMBL ID | 1625385 |
| SCHEMBL ID | 3114985 |
| MeSH ID | M0190144 |
Synonyms (38)
| Synonym |
|---|
| 1-(beta-hydroxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidine |
| ximedon |
| xymedone |
| n-(2-hydroxyethyl)-4,6-dimethyl-2-dehydropyrimidone |
| ximedone |
| 1-(2-hydroxyethyl)-4,6-dimethyl-2(1h)-pyrimidinone |
| 2(1h)-pyrimidinone, 1-(2-hydroxyethyl)-4,6-dimethyl- |
| xymedon |
| 14716-32-6 |
| STK709192 |
| 1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2(1h)-one |
| CHEMDIV2_002153 |
| HMS1375B19 |
| 1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2-one |
| A808941 |
| 1-(2-hydroxyethyl)-4,6-dimethyl-pyrimidin-2-one |
| 1-(2-hydroxyethyl)-4,6-dimethyl-2-pyrimidinone |
| AKOS003653285 |
| BBL009801 |
| 9prf0r9jsf , |
| unii-9prf0r9jsf |
| SCHEMBL3114985 |
| 4,6-dimethyl-1-(2-hydroxyethyl)pyrimidin-2(1h)-one |
| AT-057/40905231 |
| CHEMBL1625385 |
| 1-(2-hydroxy-ethyl)-4,6-dimethyl-1h-pyrimidin-2-one |
| 1-(2-hydroxyethyl)-4,6-dimethyl-2(1h)-pyrimidinone # |
| mfcd02102216 |
| 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydropyrimidin-2-one |
| 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihyd-ropyrimidin-2-one |
| VS-02189 |
| DTXSID20933048 |
| 1-(2-hydroxyethyl)-4,6-dimethyl-1h-pyrimidin-2-one |
| xymedon [who-dd] |
| n-(.beta.-hydroxyethyl)-4,6-dimethyl-2-pyrimidone |
| AT19347 |
| EN300-6735528 |
| CS-0064159 |
Research Excerpts
Treatment
Treatment with xymedon, a regeneration stimulator, led to a 48.5% increase in the number of surviving NF200+ neurons by day 30 after ligation of the nerve and a 50.7% increase by day 90.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The Xymedone-treated patients developed fewer side effects due to basic antibacterial chemotherapy and showed more rapid culture conversion, resolution of pulmonary infiltration and closure of destructive cavities." | ( [Use of systemic immunomodulator xymedone in distructive pulmonary tuberculosis]. Cherepnev, GV; Firsov, OV; Sabirova, LA; Slabnov, IuD; Vizel', AA, 2000) | 1.07 |
| "Treatment with xymedon, a regeneration stimulator, led to a 48.5% increase in the number of surviving NF200+ neurons by day 30 after ligation of the nerve and a 50.7% increase by day 90." | ( Effect of stimulation of nerve regeneration on posttraumatic neuronal survival in dorsal root ganglia. Chelyshev, YA; Raginov, IS, 2002) | 0.65 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results confirmed the efficiency and correctness of using allo-metrical method for extrapolation of pharmacokinetic data for tentative evaluation of drug parameters in humans by the results of preclinical trials on animals." | ( Interspecies pharmacokinetics of xymedon. Garmonov, SY; Pogorel'tsev, VI; Polekhina, OV; Reznik, VS, 2005) | 0.61 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " The positive results of experimental studies and clinical observations suggest that wound adapters have promises in practical application, transtissue device-aided vulnosynthesis in combination with topical pyrimidine derivatives, such as ximedon, shows great opportunities in soft tissue lesions." | ( [Adaptation-reposition technological means in combination with a bioactive preparation Ximedon for stimulation of wound healing]. Diatlov, EE; Garaev, VN; Guryleva, AA; Izmaĭlov, GA; Izmaĭlov, SG; Kedrin, MIu; Muslinkin, AA; Pashkurov, NG; Reznik, VS, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effect of systemic administration of synthetic pyrimidine derivatives, xymedon and compounds 29D and 34D, was studied in rats with experimental dosed contusion spinal cord injury." | ( New Xymedon Analogues for Stimulation of Posttraumatic Regeneration of the Spinal Cord in Rats. Chelyshev, YA; Galyametdinova, IV; Knni, KS; Kolesnikov, PE; Povysheva, TV; Reznik, VS; Semenov, VE, 2016) | 1.23 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (32)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.88) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 3 (9.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 15.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (15.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (8.16%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 45 (91.84%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||